Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasm Female × pyrotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 HER2-positive Breast Cancer 15 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Brain Neoplasms 3 Advanced Breast Cancer 3 HER2-positive Metastatic Breast Cancer 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1 Estrogen Receptor-positive Breast Cancer 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1

Interventions

Fulvestrant 2 venetoclax 1 pyrotinib 1 pertuzumab 1 penpulimab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06234137 2024-01-31

neoPICD

First Affiliated Hospital of Wenzhou Medical University

Phase NA Recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡